Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production

Scandinavian Journal of Immunology

Volumn 53, Issue 2, 2001, Pages 184-191

  Jorgensen P F ^a,b,c,d   Wang, J E ^a,b,c,d   Almlof M ^a,b,c,d   Solberg, R ^a,b,c,d   Okkenhaug, C ^a,b,c,d   Scholz, T ^a,b,c,d   Thiemermann, C ^a,b,c,d   Foster, S J ^a,b,c,d   Aasen, A O ^a,b,c,d  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; PEPTIDOGLYCAN; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIAL INFECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INHIBITION KINETICS; NORMAL HUMAN; PRIORITY JOURNAL; SEPSIS;

EID: 0035125938     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2001.00862.x     Document Type: Article

References (49)

1. Infectious diseases in the liver transplant recipient
2. Bacterial infections after liver transplantation
3. Immunopharmacology of rapamycin
4. Rapamycin (AY-22,989), a new antifungal antibiotic. II Fermentation, isolation and characterization
5. Sirolimus (rapamycin) -based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
6. Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation
7. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Thl cytotoxic cytokines
8. Innate immunity: The virtues of a nonclonal system of recognition
9. Sepsis: Lessons learned in the last century and future directions
10. Septic shock in critically ill patients: Aetiology, management and outcome
11. Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis
12. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin
13. Binding of bacterial peptidoglycan to CD14
14. CD14: Cell surface receptor and differentiation marker
15. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans
16. Peptidoglycan and teichoic acid from Staphylococcus epidermidis stimulate human monocytes to release tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6
17. Macrophage response to bacteria: Induction of marked secretory and cellular activities by lipoteichoic acids
18. Grampositive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes
19. Stimulation of monokine production by lipoteichoic acids
20. Lipoteichoic acid acts as an antagonist and an agonist of lipopolysaccharide on human gingival fibroblasts and monocytes in a CD14-dependent manner
21. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2
22. The Toll-receptor family and control of innate immunity
23. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
24. Interleukin-10
25. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: Identification of interleukin-10 as a major functional deactivator of human monocytes
26. Analysis of the autolysins of Bacillus subtilis 168 during vegetative growth and differentiation by using renaturing polyacrylamide gel electrophoresis
27. Structural analysis of Bacillus subtilis 168 endospore peptidoglycan and its role during differentiation
28. Cytokine modulation in experimental endotoxemia: Characterisation of an ex vivo whole blood model
29. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes
30. Heparin coating reduces cell activation and mediator release in an in vitro venovenous bypass model for liver transplantation
31. Autocrine and paracrine regulation of human T cell IL-10 production
32. Involvement of adenylate cyclase and p70 (S6)-kinase activation in IL-10 up-regulation in human monocytes by gp41 envelope protein of human immunodeficiency virus type 1
33. Expression of CD14 corrects the slow response to lipopolysaccharide in the 1B8 mutant of the B cell lymphoma 70Z/3
34. Modulation by lipopolysaccharide of inflammatory cytokine production by two T cell lines
35. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14
36. Soluble CD14 participates in the response of cells to lipopolysaccharide
37. Cutting edge: Toll-like receptor 4 (TLR4) -deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product
38. Gene expressions of lipopolysaccharide receptors, toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes
39. Lack of IL-10 and IL-13 production by human polymorphonuclear neutrophils
40. Rapamycin (sirolimus, rapamune)
41. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF- alpha: Role of the p38 and p42/44 mitogen-activated protein kinases
42. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance
43. Cyclosporin A inhibits the in vivo production of interleukin-1beta and tumour necrosis factor alpha, but not interleukin-6, by a T-cell- independent mechanism
44. Cyclosporin a modulation of tumor necrosis factor gene expression and effects in vitro and in vivo
45. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level
46. Transcription factors of the NFAT family: Regulation and function
47. Function and activation of NF-kappa B in the immune system
48. Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B
49. A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: Molecular cloning, sequencing, characterization, and chromosomal assignment